Floatz logo

Degarelix

Estrogen Deficiency

University of Colorado, Denverprotein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Estrogen Deficiency cohort.

Asset / SponsorPhaseRating
17-beta-estradiol
University of Colorado, Denver
Phase 4BB
TESTOSTERONE UNDECYLATE
University of Sao Paulo General Hospital
Phase 3B
LEUPROLIDE
Pennington Biomedical Research Center
D

Same molecule, other indications

Degarelix is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
prostate cancerDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →